Evidence map›Paper›PMID 34296206›Full record

ArticleCell reports methods2021

KiRNet: Kinase-centered network propagation of pharmacological screen results.

Thomas Bello, Marina Chan, Martin Golkowski, Andrew G Xue, Nithisha Khasnavis, Michele Ceribelli, Shao-En Ong, Craig J Thomas, Taranjit S Gujral

Open access · goldAbstract read
In one paragraph

Article in Cell reports methods, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. A systems approach identifies MERTK as a therapeutic vulnerability in ZFTA-RELA-driven ependymomas.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Thomas BelloHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Marina ChanHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Martin GolkowskiDepartment of Pharmacology, University of Washington, Seattle, WA 98195-7275, USA.
Andrew G XueHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Nithisha KhasnavisHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Michele CeribelliDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA.
Shao-En OngDepartment of Pharmacology, University of Washington, Seattle, WA 98195-7275, USA.
Craig J ThomasDivision of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), Bethesda, MD, USA.
Taranjit S GujralHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
University of Washington · USFred Hutch Cancer Center · USNational Center for Advancing Translational Sciences · US

Funding

Interdisciplinary Tranining in Cancer ResearchT32CA080416 · NCI · UNIVERSITY OF WASHINGTON · PI STODDARD, BARRY L. · 1998 to 2023
$9.7M
High-Performance Compute Cluster for Comprehensive Cancer and Infectious Diseases ResearchS10OD028685 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI BRADLEY, PHILIP · 2020 to 2020
$2.0M
Supplement to DEFINING PATHWAY-SPECIFIC KINASE SIGNALING MODULES WITH PROTEOMICSR01GM129090 · NIGMS · UNIVERSITY OF WASHINGTON · PI ONG, SHAO-EN · 2019 to 2022
$1.7M
A NanoLC-Orbitrap Tribrid Instrument for Comprehensive Proteomics AnalysesS10OD021502 · OD · UNIVERSITY OF WASHINGTON · PI ONG, SHAO-EN · 2017 to 2017
$906k
NCI NIH HHS T32 CA080416NIGMS NIH HHS R01 GM129090NIH HHS S10 OD021502NIH HHS S10 OD028685
6 · The paper itself

Abstract

The ever-increasing size and scale of biological information have popularized network-based approaches as a means to interpret these data. We develop a network propagation method that integrates kinase-inhibitor-focused functional screens with known protein-protein interactions (PPIs). This method, dubbed KiRNet, uses an a

Indexed as

Antineoplastic AgentsNeoplasmsHumansAntineoplastic Agents

Identifiers

PMID34296206
PMCPMC8294099
OpenAlexW3172815341

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.